Derisk development and clinical trials early

Many therapeutics rely on immunological responses, whether directly as an antibody or indirectly by triggering immune responses from the patient after vaccination. Being able to test these therapeutics in more native conditions (e.g. whole blood) from target binding to immune cell respons allows to develop better and safer therapeutics ready for a stronger filing. It opens the possibility of immune based patient selection and personalized medicine.

Reach out to Vixen Bio and we will share our experts and access to technologies in the format appropriate for your drug development or clinical trial phase.